NASDAQ:STRO - Sutro Biopharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.37 -0.32 (-2.99 %) (As of 04/21/2019 10:04 AM ET)Previous Close$10.37Today's Range$10.10 - $11.2652-Week Range$8.50 - $15.90Volume24,606 shsAverage Volume17,596 shsMarket Capitalization$237.68 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Receive STRO News and Ratings via Email Sign-up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STRO Previous Symbol CUSIPN/A CIKN/A Webwww.sutrobio.com Phone650-392-8412Debt Debt-to-Equity RatioN/A Current Ratio5.76 Quick Ratio5.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$38.42 million Price / Sales6.19 Cash FlowN/A Price / Cash FlowN/A Book Value($6.58) per share Price / Book-1.58Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees141 Outstanding Shares22,920,000Market Cap$237.68 million Next Earnings Date7/1/2019 (Estimated) OptionableNot Optionable Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions What is Sutro Biopharma's stock symbol? Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO." How were Sutro Biopharma's earnings last quarter? Sutro Biopharma Inc (NASDAQ:STRO) released its earnings results on Wednesday, November, 14th. The company reported ($21.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $21.10. The firm earned $7.84 million during the quarter. View Sutro Biopharma's Earnings History. When is Sutro Biopharma's next earnings date? Sutro Biopharma is scheduled to release their next quarterly earnings announcement on Monday, July 1st 2019. View Earnings Estimates for Sutro Biopharma. What price target have analysts set for STRO? 4 brokerages have issued 12 month price objectives for Sutro Biopharma's shares. Their forecasts range from $22.00 to $28.00. On average, they expect Sutro Biopharma's stock price to reach $24.3333 in the next year. This suggests a possible upside of 134.7% from the stock's current price. View Analyst Price Targets for Sutro Biopharma. What is the consensus analysts' recommendation for Sutro Biopharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sutro Biopharma. Has Sutro Biopharma been receiving favorable news coverage? News stories about STRO stock have been trending somewhat positive on Sunday, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sutro Biopharma earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. Who are some of Sutro Biopharma's key competitors? Some companies that are related to Sutro Biopharma include BioCryst Pharmaceuticals (BCRX), Twist Bioscience (TWST), Cellectis (CLLS), NanoString Technologies (NSTG), Vericel (VCEL), Nightstar Therapeutics (NITE), BAVARIAN NORDIC/S (BVNRY), Osiris Therapeutics (OSIR), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Heska (HSKA), Acorda Therapeutics (ACOR), DBV TECHNOLOGIE/S (DBVT), Mesoblast (MESO) and Avrobio (AVRO). What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Anavex Life Sciences (AVXL), Krystal Biotech (KRYS), Momo (MOMO), Principia Biopharma (PRNB), Omnicom Group (OMC), Alcentra Capital (ABDC), Arca Biopharma (ABIO), AcelRx Pharmaceuticals (ACRX), Adobe (ADBE) and Adomani (ADOM). Who are Sutro Biopharma's key executives? Sutro Biopharma's management team includes the folowing people: Mr. William J. Newell, CEO & Director (Age 61)Dr. Trevor J. Hallam, Chief Scientific Officer (Age 60)Dr. Arturo M. Molina, Chief Medical Officer (Age 60)Dr. James R. Swartz Sc.D., Ph.D., Founder and Member of Scientific Advisory BoardMr. Edward C. Albini, CFO & Sec. (Age 61) When did Sutro Biopharma IPO? (STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. When did the company's lock-up period expire? Sutro Biopharma's lock-up period expired on Tuesday, March 26th. Sutro Biopharma had issued 5,667,000 shares in its public offering on September 27th. The total size of the offering was $85,005,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period. How do I buy shares of Sutro Biopharma? Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sutro Biopharma's stock price today? One share of STRO stock can currently be purchased for approximately $10.37. How big of a company is Sutro Biopharma? Sutro Biopharma has a market capitalization of $237.68 million and generates $38.42 million in revenue each year. The company earns $-35,320,000.00 in net income (profit) each year or ($6.13) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe. What is Sutro Biopharma's official website? The official website for Sutro Biopharma is http://www.sutrobio.com. How can I contact Sutro Biopharma? Sutro Biopharma's mailing address is 310 UTAH AVE. SUITE 150, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-392-8412. MarketBeat Community Rating for Sutro Biopharma (NASDAQ STRO)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 34 (Vote Outperform)Underperform Votes: 48 (Vote Underperform)Total Votes: 82MarketBeat's community ratings are surveys of what our community members think about Sutro Biopharma and other stocks. Vote "Outperform" if you believe STRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STRO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/21/2019 by MarketBeat.com StaffFeatured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?